Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Qin, Si‐Yong; Zhang, Aiqing; Zhang, Xian‐Zheng

doi:10.1002/smll.201802417

Cited by 109 publications

(57 citation statements)

References 200 publications

(272 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Figure 1c and Figure S1a, the typical 1 O 2 signal produced by HE/HF under 671 nm laser irradiation indicated its potential for application in PDT. 1 O 2 was chemically detected in HE/HF by using DPBF in DMF as a trapping agent under the 532 nm laser (Figure 1d), and the calculated 1 O 2 QY of HE/HF was 0.27/0.31.…”

Section: Resultsmentioning

confidence: 99%

“…Cancer, as one of the main causes of death worldwide, has been a motivation for remarkable efforts in many scientific fields. [1][2] In comparison with classic cancer therapeutic modalities, phototherapies, involving photodynamic therapy (PDT) and photothermal therapy (PTT), have provided possible therapeutic effects because of their specific characteristics, such as minimal invasion, precise therapy, and minimal side effects. [3][4][5][6] PDT involves photosenstizer (PS), oxygen (O 2 ), and light at a specific wavelength.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Near‐Infrared Hypocrellin Derivatives for Synergistic Photodynamic and Photothermal Therapy

Ding

Liu

et al. 2020

Chemistry An Asian Journal

View full text Add to dashboard Cite

Hypocrellin B (HB) derived from naturally produced hypocrellins has attracted considerable attention in photodynamic therapy (PDT) because of its excellent photosensitive properties. However, the weak absorption within a "phototherapy window" (600-900 nm) and poor water solubility of HB have limited its clinical application. In this study, two HB derivatives (i. e., HE and HF) were designed and synthesized for the first time by introducing two different substituent groups into the HB structure. The obtained derivatives showed a broad absorption band covering the near-infrared (NIR) region, NIR emission (peaked at 805 nm), and singlet oxygen quantum yields of 0.27/0.31. HE-PEG-NPs were also prepared using 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-mPEG2000) to achieve excellent dispersion in water and further explored their practical applications. HE-PEG-NPs not only retained their 1 O 2-generating ability, but also exhibited a photothermal conversion efficiency of 25.9%. In vitro and in vivo therapeutic results revealed that the synergetic effect of HE-PEG-NPs on PDT and photothermal therapy (PTT) could achieve a good performance. Therefore, HE-PEG-NPs could be regarded as a promising phototheranostic agent.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Near‐Infrared Hypocrellin Derivatives for Synergistic Photodynamic and Photothermal Therapy

Ding

Liu

et al. 2020

Chemistry An Asian Journal

View full text Add to dashboard Cite

show abstract

“…The mini‐Ussing chamber assay is a conventional in vitro system to evaluate the transport index, which is used to estimate the intestinal mucosa permeation of drugs or nutrition . For the Ussing chamber model, the change of drug concentration during incubation and the tissue accumulation of a drug, which are crucial factors in predicting the fraction of absorbed drug, can both be taken into account.…”

Section: Resultsmentioning

confidence: 99%

“…The mini-Ussing chamber assay is a conventional in vitro system to evaluate the transport index, which is used to estimate the intestinal mucosa permeation of drugs or nutrition. [32] For the Ussing chamber model, the change of drug concentration during incubation and the tissue accumulation of a drug, which are crucial factors in predicting the fraction of absorbed drug, can both be taken into account. In this work, we attempted to apply such mini-Ussing chamber assay to estimate the bladder mucosal penetration abilities of free MPI and the MPI-loading NPs prepared with different feeding ratios (Figure 2a).…”

Section: Introductionmentioning

confidence: 99%

Fluorinated Polymer Mediated Transmucosal Peptide Delivery for Intravesical Instillation Therapy of Bladder Cancer

Lei

Wang

et al. 2019

Small

View full text Add to dashboard Cite

Surgical intervention combined with intravesical instillation of chemotherapeutics to clear residual cancer cells after operation is the current standard treatment method for bladder cancer. However, the poor bioavailability of active pharmaceutical ingredients for bladder cancer cells on account of the biological barriers of bladder mucosa, together with significant side effects of currently used intravesical medicine, have limited the clinical outcomes of localized adjuvant therapy for bladder cancer. Aiming at improved intravesical instillation therapy of bladder cancer, a fluorinated polyethylenimine (F‐PEI) is employed here for the transmucosal delivery of an active venom peptide, polybia‐mastoparan I (MPI), which shows selective antiproliferative effect against various bladder cancer cell lines. Upon simple mixing, MPI and F‐PET would coassemble to form stable nanoparticles, which show greatly improved cross‐membrane and transmucosal penetration capacities compared with MPI alone or nonfluorinated MPI/PEI nanoparticles. MPI/F‐PEI shows higher in vivo tumor growth inhibition efficacy for local treatment of a subcutaneous tumor model. More excitingly, as further demonstrated in an orthotopic bladder cancer model, MPI/F‐PEI offers remarkably improved therapeutic effects compared to those achieved by free MPI or the first‐line bladder cancer drug mitomycin C. This work presents a new transmucosal delivery carrier particularly promising for intravesical instillation therapy of bladder cancer.

show abstract

“…GSH is one of the most abundant cancer-associated physiological stimuli, and it plays an important role in the regulation of intracellular redox homeostasis. [30] GSH is involved in controlling protein folding by regulating the formation and rupture of disulfide bonds. [31] Notably, the concentration of GSH in tumor cells is generally higher than in normal cells, which is reported to be 5-10 mM.…”

Section: Gsh-activatable Photo-immunometabolic Therapymentioning

confidence: 99%

Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy

Zhang

2020

Small Structures

View full text Add to dashboard Cite

Cancer immunotherapy that stimulates the patient's immune system to eradicate cancer cells is a revolutionary strategy for the treatment of malignancies. [1] Compared to traditional chemotherapy and radiotherapy, which kill both cancer cells and normal cells, cancer immunotherapy can activate antitumor immune response to specifically target and eliminate cancer cells. [2] In general, the generation of antitumor immune response consists of a series of immunological processes. [3] First, tumor-associated antigens (TAAs) and danger-associated molecular patterns (DAMPs) are released from dying tumor cells. [4] Then, TAAs are captured by antigen-presenting cells (APCs), and DAMPs induce the activation and maturation of APCs. Activated APCs travel to lymph nodes and present TAAs on major histocompatibility complex I (MHC I) and MHC II molecules to T cells, leading to the activation of T cells. [5] Finally, activated T cells infiltrate the tumor tissues, recognize TAA-specific tumor cells, and release effector molecules (granzyme B and perforin) to kill tumor cells. [6] Up to now, several immunotherapies (e.g., immune checkpoint blockade (ICB), adoptive cell transfer, and cancer vaccine) that focus on the initiation and activation of antitumor immunity via various targets or mechanisms have been developed and achieved some progress in preclinical research and clinical translation. [7] Immunometabolic cancer therapy is an emerging therapeutic strategy that modulates tumor metabolic signaling pathways to activate immune cells to fight against tumors (Scheme 1a). [8] The proliferation and growth of cells generally involve a network of metabolic reactions (such as glycolysis, the tricarboxylic acid cycle, and amino acid metabolism). [9] In tumor cells, the dysregulation of cellular metabolic programs (e.g., nutrient limitation, immunosuppressive metabolites, and inhibitory immunometabolic signaling pathways) can lead to the failure of the immune system to fight against the tumor. [10] Tumor metabolic programs not only reflect the cellular state, but also play essential roles to restrict antigen presentation, initiate immune suppression or exhaustion, and impair the function of immune cells (including tumor-associated macrophages (TAMs), natural killer (NK) cells, effector T (T eff) cells, and regulatory T (T reg) cells). [11] Thereby, immunometabolic therapy that targets or modulates metabolic circuits to reprogram cancer metabolism can greatly attenuate tumor progression and reinvigorate antitumor immunity. [12] For example, inhibition of lactic acid production has been utilized to reduce tumor growth and unleash antitumor immunity; blockade of glutamine catabolism can inhibit the proliferation of tumor cells and recover the function and activity of TAMs and T eff cells. [8c] Thus, the development and advancement of immunometabolic therapies holds promise to improve the effectiveness of the treatment of cancer. Despite the progress, the clinical translation of cancer immunotherapies still faces some obstacles, such as immu...

show abstract

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Cited by 109 publications

References 200 publications

Near‐Infrared Hypocrellin Derivatives for Synergistic Photodynamic and Photothermal Therapy

Near‐Infrared Hypocrellin Derivatives for Synergistic Photodynamic and Photothermal Therapy

Fluorinated Polymer Mediated Transmucosal Peptide Delivery for Intravesical Instillation Therapy of Bladder Cancer

Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy

Contact Info

Product

Resources

About